ImpediMed Revenue Rises, But New Contracts Fall As BCRL Sales Miss Expectations
IPD: $0.004 -11.11% · MC: $15M
ImpediMed reported Q1 FY27 revenue up 6% from the prior quarter and annual recurring revenue up 12% year on year on a constant-currency basis, while contract value fell from the previous quarter as fewer contracts came up for renewal. Operating cash outflow narrowed by $2 million quarter on quarter, with $12 million in cash at quarter-end; the company said breast cancer-related lymphoedema sales fell short of expectations and it is rebuilding its sales team. The quarter also saw renewed-contract prices rise 18% on average, alongside new US accreditation standards requiring lymphoedema assessment programs at breast centres.

Comments